Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Pain, Intractable 1Cancer Pain 1

Interventions

Specimen Handling 17Biopsy 9Magnetic Resonance Spectroscopy 8X-Rays 5Cyclophosphamide 5venetoclax 4fludarabine 4dexamethasone acetate 4dexamethasone 21-phosphate 4auricularum 4Dexamethasone 4Calcium Dobesilate 4carfilzomib 3Hyaluronoglucosaminidase 3sargramostim 2pomalidomide 2decitabine and cedazuridine drug combination 2daratumumab 2balstilimab 2Whole-Body Irradiation 2Stem Cell Transplantation 2Photons 2Melphalan 2Fluorodeoxyglucose F18 2Doxorubicin 2Cytarabine 2Colony-Stimulating Factors 2Busulfan 2trastuzumab deruxtecan 1sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × NIH × resiniferatoxin × Clear all
NCT02522611 2026-06-01

Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain

National Institutes of Health Clinical Center (CC)

Phase 1/2 Not yet recruiting
30 enrolled

Cancer Pain, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡